05:39:39 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.

Kalender

2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 Ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 Ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 Ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2
2022-02-18 08:38:29

Inhalation Research Services, ISAB's contract research organization, has signed a contract worth 584 000 SEK with a leading nanotechnology company that specializes in developing new inhalable nanoporous particles for drug delivery. The client has chosen ISAB's unique intratracheal in vivo exposure module for its research project, due to its proven precision and reliability.

The development of nanoparticles for drug delivery is a fast-moving and high-potential research area within the pharmaceutical industry. A leading company in the field has now chosen Inhalation Research Services for a contract research project that is exploring the development of inhalable nanoporous particles for drug delivery.

The company wishes to evaluate how test particles dissolve in the lung in vivo, and how quickly they move into the bloodstream. To do so, they have chosen to use ISAB's intratracheal in vivo exposure module. This delivers aerosol directly to the lungs of an individual test rodent, bypassing its nose, whilst carefully monitoring aerosol concentration and individual breathing patterns. The method delivers voluminous data with exceptionally high precision.

ISAB CEO Manoush Masarrat: "We are pleased that this company, a clear leader in its field, has chosen our technology because of its proven precision and reliability. When finalized, we certainly aim to expand our cooperation and carry out more projects further down the line."